Recently, comprehensive genomic analyses have described the relative frequency of tuberous sclerosis complex 1 and 2 (TSC1/TSC2) gene mutations, drawing attention to the role of the mammalian target of the rapamycin (mTOR) pathway in different renal tumors. Here, TSC1 is linked to Renal neoplasm.